Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04943900 · ClinicalTrials.gov registry record · Phase 1
A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 67
- Enrollment target
NCT04943900 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 67 participants.
The verdict
NCT04943900, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 67 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
Interventions
- DRUG Nivolumab
- DRUG BMS-986416
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 67 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2025-02-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04943900
The ClinicalTrials.gov registry entry for NCT04943900 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 67 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04943900 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04943900 about?
NCT04943900 is a clinical study titled "A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors". The purpose of this study is to evaluate the safety, tolerability, drug effects, drug levels and preliminary antitumor activity of BMS-986416 when administered alone and in combination with Nivolumab in participants with select advanced solid tumors.
What is the current status of trial NCT04943900?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 67 participants. The study started on 2021-08-09. Estimated completion is 2025-02-27.
What interventions are being tested in trial NCT04943900?
The interventions under investigation include: Nivolumab (DRUG), BMS-986416 (DRUG).
Who is sponsoring clinical trial NCT04943900?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.